Drugmaker Eli Lilly said that in Phase 3 studies of over 550 adults, their oral GLP-1 pill, orforglipron, could reduce ...

A daily pill from Eli Lilly lowered blood sugar levels and induced weight loss in people with Type 2 diabetes, the company announced Thursday.

Orforglipron, a once-daily glucagon-like peptide-1 (GLP-1) receptor agonist, significantly reduced hemoglobin A1c (HbA1c) in adults with type 2 diabetes (T2D) and inadequate glycemic control with diet ...

A daily pill from drugmaker Eli Lilly has shown safety results comparable to the leading injectable GLP-1 drugs Mounjaro and ...

Eli Lilly has announced a daily pill that lowers blood sugar levels and promotes weight loss in individuals suffering from ...

Eli Lilly (NYSE:LLY) rose about 14% in premarket trade Thursday after reporting positive top-line results from a late-stage trial of its experimental oral GLP-1 drug, orforglipron, in adults with type ...

Eli Lilly's oral GLP-1 drug orforglipron met key Phase 3 goals in type 2 diabetes, lowering A1C and weight with a favorable ...

Eli Lilly reported positive results from Phase 3 ACHIEVE-1 trial of orforglipron for type 2 diabetes, meeting primary endpoint of A1C reduction. Analysts see potential for sales of $10 billion by 2030 ...

A screening initiative in West Chicago found that 50% of food-insecure individuals had abnormal A1c levels, with many unaware ...

Eli Lilly has met its goal of achieving semaglutide-like efficacy with an oral GLP-1 drug. | Eli Lilly has met its goal of ...

Shares of Eli Lilly and Company (NYSE:LLY) surged 12.5% following the announcement of positive Phase 3 trial results for orforglipron, a pioneering oral medication for type 2 diabetes.

Eli Lilly’s shares shot up 11% pre-market on Thursday after orforglipron became the first small-molecule GLP-1 drug to ace a ...